All the Active Ingredient Drugs
Bruton’s Tyrosine Kinase Inhibitor. acalabrutinib 100 mg. FC tab 60 X 100mg
For pts. with MCL, CLL, or SLL.
As monother. or in combin. with other medicinal prod., 100 mg acalabrutinib 2/d. (equiv. to daily dose of 200 mg.) until dis. progr. or unacceptable tox.
Tmt. of adult pts. with mantle cell lymphoma (MCL) who have received at least one prior ther. Tmt. of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combin. with bendamustine and rituximab for tmt. of adult pts. with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplant. (HSCT). Tmt. previously untreated chronic lymphocytic leukemia in combin. with venetoclax with or w/o obinutuzumab.
C/I: Hypersens.
